SCHEMBL1462845

SCHEMBL1462845

NC(=O)CC[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8011163 0.85
SCHEMBL2077058 0.82
SCHEMBL8810939 0.80 KMT2A (0.40)
SCHEMBL8018189 0.80 KMT2A (0.40)
SCHEMBL8812767 0.80 KMT2A (0.40)
SCHEMBL8018462 0.80 KMT2A (0.40)
SCHEMBL8812331 0.80 KMT2A (0.40)
SCHEMBL16915245 0.80 KMT2A (0.40)
SCHEMBL16915251 0.80 KMT2A (0.40)
SCHEMBL2122700 0.73 CES2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190031618-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2019-01-31 US claimed
US-10118900-B2 Benzimidazole derivatives useful as CB-1 inverse agonists JANSSEN PHARMACEUTICA NV (BE) 2018-11-06 US claimed
WO-2017035114-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 WO claimed
US-20170057929-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 US claimed
CN-102049048-A Method of treatment or prophylaxis SPINIFEX PHARM PTY LTD 2011-05-11 CN claimed
US-7608602-B2 Gemcitabine prodrugs, pharmaceutical compositions and uses thereof XENOPORT, INC. (US) 2009-10-27 US claimed
CN-101443001-A Methods of treating or preventing inflammatory pain UNIV QUEENSLAND (AU) 2009-05-27 CN claimed
EP-1506175-B1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-01 EP claimed
US-20080021208-A1 Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof XENOPORT, INC. (US) 2008-01-24 US claimed
CN-101087619-A methods of treatment or prevention UNIV QUEENSLAND (AU) 2007-12-12 CN claimed
US-20040082639-A1 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-04-29 US claimed
WO-2003097609-A1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2003-11-27 WO claimed
EP-0333174-B1 Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1996-05-08 EP claimed
US-5187156-A D-Tryptophan- and Phenylalanine-containing tripeptides as tachykinin antagonists; asthma FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-02-16 US claimed
US-5182264-A Angiotensin II receptor blockers as antiglaucoma agents SCHERING CORPORATION (US) 1993-01-26 US claimed
EP-0333174-A2 Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-09-20 EP claimed
EP-0025897-B1 PEPTIDES AND PROCESS FOR THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1984-03-28 EP claimed
US-4420424-A New peptides and a process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1983-12-13 US claimed
EP-0025897-A2 Peptides and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1981-04-01 EP claimed
US-4013791-A MEDICAL DIAGNOSIS HOECHST AKTIENGESELLSCHAFT (DT) 1977-03-22 US claimed